<DOC>
	<DOCNO>NCT02020499</DOCNO>
	<brief_summary>This long term study evaluate common therapeutic algorithm possible predictive parameter Somatuline Autogel treatment patient Acromegaly .</brief_summary>
	<brief_title>Predictive Factors Study</brief_title>
	<detailed_description />
	<mesh_term>Acromegaly</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Diagnosis Acromegaly . Males females age 18 year old . Signed informed consent ( patient must give consent collection retrospective data ) . Patients surgery may enter study 3 month postsurgery evaluate duration study . With intention treat ATG ( decision prescribe ATG make prior inclusion study ) already treat ATG . If already treat ATG : Previous ATG treatment maximum 3 month . AND Minimum data available ( demographic data , disease history include previous treatment , GH , IGF1 level baseline treatment applicable ) . Not receive Dopamine Agonists medical therapy ( Pegvisomant , somatostatin analogue ) treatment symptom control acromegaly . The subject radiotherapy last 5 year . The subject surgery last 3 month . The subject already include study . Participation interventional trial , receive experimental drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>